Henry Eric, Cores Jhon, Hensley M Taylor, Anthony Shirena, Vandergriff Adam, de Andrade James B M, Allen Tyler, Caranasos Thomas G, Lobo Leonard J, Cheng Ke
Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, and North Carolina State University, Raleigh, North Carolina, USA.
Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Stem Cells Transl Med. 2015 Nov;4(11):1265-74. doi: 10.5966/sctm.2015-0062. Epub 2015 Sep 10.
Lung diseases are devastating conditions and ranked as one of the top five causes of mortality worldwide according to the World Health Organization. Stem cell therapy is a promising strategy for lung regeneration. Previous animal and clinical studies have focused on the use of mesenchymal stem cells (from other parts of the body) for lung regenerative therapies. We report a rapid and robust method to generate therapeutic resident lung progenitors from adult lung tissues. Outgrowth cells from healthy lung tissue explants are self-aggregated into three-dimensional lung spheroids in a suspension culture. Without antigenic sorting, the lung spheroids recapitulate the stem cell niche and contain a natural mixture of lung stem cells and supporting cells. In vitro, lung spheroid cells can be expanded to a large quantity and can form alveoli-like structures and acquire mature lung epithelial phenotypes. In severe combined immunodeficiency mice with bleomycin-induced pulmonary fibrosis, intravenous injection of human lung spheroid cells inhibited apoptosis, fibrosis, and infiltration but promoted angiogenesis. In a syngeneic rat model of pulmonary fibrosis, lung spheroid cells outperformed adipose-derived mesenchymal stem cells in reducing fibrotic thickening and infiltration. Previously, lung spheroid cells (the spheroid model) had only been used to study lung cancer cells. Our data suggest that lung spheroids and lung spheroid cells from healthy lung tissues are excellent sources of regenerative lung cells for therapeutic lung regeneration.
The results from the present study will lead to future human clinical trials using lung stem cell therapies to treat various incurable lung diseases, including pulmonary fibrosis. The data presented here also provide fundamental knowledge regarding how injected stem cells mediate lung repair in pulmonary fibrosis.
肺部疾病是极具破坏性的病症,根据世界卫生组织的数据,其位列全球五大死因之一。干细胞疗法是一种有前景的肺再生策略。此前的动物和临床研究主要聚焦于使用(来自身体其他部位的)间充质干细胞进行肺再生治疗。我们报告了一种从成年肺组织中快速且高效地生成治疗性肺驻留祖细胞的方法。健康肺组织外植体生长出的细胞在悬浮培养中自聚集形成三维肺球体。无需进行抗原分选,肺球体就能重现干细胞微环境,并包含肺干细胞和支持细胞的天然混合物。在体外,肺球体细胞可大量扩增,能形成类似肺泡的结构并获得成熟的肺上皮表型。在博来霉素诱导的肺纤维化严重联合免疫缺陷小鼠中,静脉注射人肺球体细胞可抑制细胞凋亡、纤维化和炎症浸润,但促进血管生成。在肺纤维化的同基因大鼠模型中,肺球体细胞在减轻纤维化增厚和炎症浸润方面比脂肪来源的间充质干细胞表现更优。此前,肺球体细胞(球体模型)仅用于研究肺癌细胞。我们的数据表明,来自健康肺组织的肺球体和肺球体细胞是用于治疗性肺再生的优秀肺再生细胞来源。
本研究结果将推动未来使用肺干细胞疗法治疗包括肺纤维化在内的各种难治性肺部疾病的人体临床试验。此处呈现的数据还提供了关于注入的干细胞如何介导肺纤维化中肺修复的基础知识。